Matthew Shea analyst NEEDHAM

Currently out of the existing stock ratings of Matthew Shea, 12 are a BUY (100%).

Matthew Shea

Work Performance Price Targets & Ratings Chart

Analyst Matthew Shea, currently employed at NEEDHAM, has had 79.17% of price targets met with an average potential upside of 32.29%, reached in 65 days on average.

Matthew Shea has documented 24 price targets and ratings displayed on 4 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on ASTH, Astrana Health at 05-Nov-2026.

Wall Street Analyst Matthew Shea

Analyst best performing recommendations are on PRVA (PRIVIA HEALTH GROUP).
The best stock recommendation documented was for TOI (ONCOLOGY INSTITUTE) on 3/9/2026. The price target of $5 was fulfilled within 91 days with a profit of $2.27 (83.15%), with a performance score of 9.14.

Average potential price target upside

EVH Evolent Health PRVA Privia Health Group TOI Oncology Institute ASTH Astrana Health

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 11-Aug-2026

$6

$2.57 (74.93%)

$6

1 days ago
(19-Nov-2026)

Buy Since 01-Mar-2026

$7

$3.57 (104.08%)

$6

15 days ago
(05-Nov-2026)

1/2 (50%)

$2.42 (52.84%)

134

Buy Since 02-Mar-2026

$6

$2.57 (74.93%)

$5

3 months 3 days ago
(17-Aug-2026)

1/2 (50%)

$1.42 (31.00%)

113

Buy Since 14-Nov-2016

$6

$2.57 (74.93%)

$5

3 months 4 days ago
(16-Aug-2026)

11/24 (45.83%)

$1.59 (36.05%)

1198

Hold Since 10-Aug-2026

$6

$2.57 (74.93%)

$6.75

3 months 10 days ago
(10-Aug-2026)

1/7 (14.29%)

$1.9 (46.34%)

42

Show more analysts

Please expand the browser size to see the chart

Which stock is Matthew Shea most bullish on?

Potential upside of $16.1 has been obtained for ASTH (ASTRANA HEALTH)

Which stock is Matthew Shea most reserved on?

Potential downside of $1.87 has been obtained for TOI (ONCOLOGY INSTITUTE)

What Year was the first public recommendation made by Matthew Shea?

On 2025
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?